Hans Biomed
Daily close in US$ at the latest USD/KRW close. Source: KRX via FinanceDataReader.
Hans Biomed makes human tissue implants, grafts derived from skin and bone used in surgical procedures, as well as medical devices such as thread-lift products and hair-transplant tools.
Its products are used by medical professionals, and it supplies customers both in South Korea and internationally through subsidiaries in the United States, Thailand, the United Kingdom, and other markets. Listed on KOSDAQ, South Korea's tech and small-cap exchange, the company earns the majority of its revenue from its tissue-implant product lines, with medical devices accounting for most of the remainder.
Summary is AI-generated and may contain errors · figures from DART filings
The company also has affiliated domestic entities and conducts R&D across tissue engineering and newer fields such as vascular haemostasis devices through shared research centres.
Hans Biomed in five facts
What does Hans Biomed do?
Hans Biomed makes human tissue implants, grafts derived from skin and bone used in surgical procedures, as well as medical devices such as thread-lift products and hair-transplant tools.
Where is Hans Biomed listed and in which sector?
Hans Biomed (Korean name: 한스바이오메드) trades under KRX code 042520 on KOSDAQ, the Korea Exchange's board for smaller and growth companies. It is classified in the Health Care sector, Pharmaceuticals.
How large is Hans Biomed?
Its market capitalisation was US$200M on 2026-10-21, which puts it in this site's small-cap group. US$ amounts are converted from won at 1 USD ≈ ₩1,325 (2026-10-21).
What were Hans Biomed's latest annual revenue and operating profit?
For fiscal year 2025, Hans Biomed reported revenue of US$67.8M, an operating loss of US$19.5M and a net loss of US$24.2M, per its annual report on DART (data retrieved from DART on 2026-09-08). Revenue was up 10.7% on the previous year.
Where does this data come from?
Financial statements and filings come from DART, Korea's official corporate-filing system. Share prices, market capitalisation and trading status come from KRX. Company summaries are AI-generated from the filings and may contain errors; financial figures are mapped directly from DART.
Data sources and last updated
- Filings and financial statements
- DART (dart.fss.or.kr), Korea's official corporate-filing system
- Prices, market cap, trading status
- KRX (Korea Exchange), via FinanceDataReader
- Latest annual financials
- Fiscal year 2025, data retrieved from DART on 2026-09-08
- Share price and market cap
- Close of 2026-10-21
- Currency
- US$, converted from won at 1 USD ≈ ₩1,325 (2026-10-21 close)
- Company data updated
- 2026-10-21
- Company summary
- AI-generated from filings; may contain errors. Information only, not investment advice.